LNP023

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AnemiaKidney DiseaseIga NephropathyMembranous NephropathyParoxysmal Nocturnal Hemoglobinuria

272 competitors in Anemia

#DrugCompanyPhaseTrials

1

Fludara

Sanofi

Phase 3

12

Campath

GGenzyme, a Sanofi Company

Phase 3

23

Imbruvica

PPharmacyclics LLC.

Phase 3

14

Ferrous Sulphate

VVifor Pharma

Phase 3

35

LNP023

Novartis

Phase 3

16

HX575 Epoetin Alfa

Novartis

Phase 3

17

Epoetin

Roche

Phase 3

58

HRS-5965

CChengdu Suncadia Medicine Co., Ltd.

Phase 3

19

Aranesp

Amgen

Preclinical

3810

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

52Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Paroxysmal Nocturnal Hemoglobinuria2 trials

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed·Novartis·Phase 2·NCT03896152·13 enrolled

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed·Novartis·Phase 2·NCT02534909·10 enrolled

Efficacy1 trial

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting·Novartis·Phase 3·NCT03955445·225 enrolled

Anemia1 trial

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Completed·Novartis·Phase 3·NCT04558918·97 enrolled

Kidney Disease1 trial

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Completed·Novartis·Phase 2·NCT03373461·112 enrolled

Pediatric1 trial

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Recruiting·Novartis·Phase 3·NCT06934967·12 enrolled

5 more indications

Efficacy and Safety1 trial

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Completed·Novartis·Phase 2·NCT03832114·27 enrolled

Membranous Nephropathy1 trial

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Terminated·Novartis·Phase 2·NCT04154787·37 enrolled

Cohort Study1 trial

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

Recruiting·Novartis··NCT06931691·80 enrolled

Primary IgA Nephropathy1 trial

A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301

Active, not recruiting·Novartis·Phase 3·NCT04557462·448 enrolled

IgA Nephropathy1 trial

SHINE-2: Iptacopan in IgA Nephropathy

Recruiting·Novartis·Phase 3·NCT04578834·580 enrolled

Details

Drug Info

Related News